The Effect of Immunoglobulin G on the Humoral Immunity in Patients with Tuberculosis/HIV Coinfection.

IF 1.5 4区医学 Q4 IMMUNOLOGY

AIDS research and human retroviruses Pub Date : 2024-04-01 Epub Date: 2024-01-31 DOI:10.1089/AID.2023.0074

Nina A Matsegora, Antonina V Kaprosh, Tetyana I Vasylyeva, Petro B Antonenko, Kateryna Antonenko

{"title":"The Effect of Immunoglobulin G on the Humoral Immunity in Patients with Tuberculosis/HIV Coinfection.","authors":"Nina A Matsegora, Antonina V Kaprosh, Tetyana I Vasylyeva, Petro B Antonenko, Kateryna Antonenko","doi":"10.1089/AID.2023.0074","DOIUrl":null,"url":null,"abstract":"<p><p>Previously, an increase in clinical effectiveness of the antituberculosis treatment (ATT) and antiretroviral therapy (ART) in case of additional immunoglobulin G (IgG) administration in patients with multidrug-resistant tuberculosis (MDR-TB)/HIV coinfection was reported. The aim of this study was to investigate the impact of IgG administration in addition to the standard second-line ATT and ART on the humoral immunity status in patients with MDR-TB/HIV coinfection immune deficiency. The study involved 52 patients living with HIV with MDR-TB coinfection and CD4+ lymphocyte cell count below 50 cells/μCL. Patients in the control group and intervention group received the second-line ATT and ART; in addition, patients in the intervention group received IgG intravenously. The humoral immunity status was evaluated by measurement of IgA, IgE, IgG, and IgM in plasma. The standard ATT and ART resulted in a two-step change in humoral immunity: IgM, IgG, IgA, and IgE levels gradually increased to a maximal level at the 5-month mark and started to gradually decrease after the 8-month mark. Addition of IgG to the standard therapy resulted in a steeper decrease in the immunoglobulin level in serum, especially IgG, compared with standard therapy alone, allowing for an earlier initiation of ART in patients in the intervention group.</p>","PeriodicalId":7544,"journal":{"name":"AIDS research and human retroviruses","volume":" ","pages":"246-252"},"PeriodicalIF":1.5000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS research and human retroviruses","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/AID.2023.0074","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/31 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Previously, an increase in clinical effectiveness of the antituberculosis treatment (ATT) and antiretroviral therapy (ART) in case of additional immunoglobulin G (IgG) administration in patients with multidrug-resistant tuberculosis (MDR-TB)/HIV coinfection was reported. The aim of this study was to investigate the impact of IgG administration in addition to the standard second-line ATT and ART on the humoral immunity status in patients with MDR-TB/HIV coinfection immune deficiency. The study involved 52 patients living with HIV with MDR-TB coinfection and CD4+ lymphocyte cell count below 50 cells/μCL. Patients in the control group and intervention group received the second-line ATT and ART; in addition, patients in the intervention group received IgG intravenously. The humoral immunity status was evaluated by measurement of IgA, IgE, IgG, and IgM in plasma. The standard ATT and ART resulted in a two-step change in humoral immunity: IgM, IgG, IgA, and IgE levels gradually increased to a maximal level at the 5-month mark and started to gradually decrease after the 8-month mark. Addition of IgG to the standard therapy resulted in a steeper decrease in the immunoglobulin level in serum, especially IgG, compared with standard therapy alone, allowing for an earlier initiation of ART in patients in the intervention group.

查看原文本刊更多论文

免疫球蛋白 G 对结核病/艾滋病毒合并感染患者体液免疫的影响。

此前曾有报道称，在耐多药结核病（MDR-TB）/艾滋病病毒（HIV）合并感染患者中额外服用 IgG 可提高抗结核疗法（ATT）和抗逆转录病毒疗法（ART）的临床疗效。本研究旨在探讨在标准二线 ATT 和 ART 治疗的基础上追加 IgG 对 MDR-TB/HIV 合并感染免疫缺陷患者体液免疫状态的影响。研究方法研究涉及 52 名合并 MDR-TB 感染、CD4+淋巴细胞计数低于 50 cells/μCL 的 HIV 感染者。对照组和干预组患者接受二线 ATT 和抗逆转录病毒疗法；此外，干预组患者静脉注射免疫球蛋白 G (IgG)。通过测量血浆中的 IgA、IgE、IgG、IgM 来评估体液免疫状态。结果显示标准抗逆转录病毒疗法和抗逆转录病毒疗法导致体液免疫发生了两步变化：IgM、IgG、IgA 和 IgE 水平在 5 个月时逐渐升高到最高水平，8 个月后开始逐渐下降。与单独使用标准疗法相比，在标准疗法中添加 IgG 可使血清中的免疫球蛋白（尤其是 IgG）水平下降得更快，从而使干预组患者更早地开始接受抗逆转录病毒疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

AIDS research and human retroviruses 医学-病毒学

CiteScore

3.10

自引率

6.70%

发文量

201

审稿时长

3-6 weeks

期刊介绍： AIDS Research and Human Retroviruses was the very first AIDS publication in the field over 30 years ago, and today it is still the critical resource advancing research in retroviruses, including AIDS. The Journal provides the broadest coverage from molecular biology to clinical studies and outcomes research, focusing on developments in prevention science, novel therapeutics, and immune-restorative approaches. Cutting-edge papers on the latest progress and research advances through clinical trials and examination of targeted antiretroviral agents lead to improvements in translational medicine for optimal treatment outcomes. AIDS Research and Human Retroviruses coverage includes: HIV cure research HIV prevention science - Vaccine research - Systemic and Topical PreP Molecular and cell biology of HIV and SIV Developments in HIV pathogenesis and comorbidities Molecular biology, immunology, and epidemiology of HTLV Pharmacology of HIV therapy Social and behavioral science Rapid publication of emerging sequence information.